drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous gene-modified CAR T cells), intravenous infusion
drug_description
An autologous, gene-modified T-cell therapy in which patient T cells are engineered to express chimeric antigen receptors targeting CD19 and a BAFF-based target, leading to antigen-dependent T-cell activation, cytokine release, and cytotoxic killing of malignant B cells in relapsed/refractory B-ALL and B-cell NHL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a chimeric antigen receptor that recognizes CD19 and a BAFF pathway target on B cells. Upon antigen engagement, the CAR T cells activate, proliferate, release cytokines, and mediate perforin/granzyme-dependent cytotoxicity to eliminate malignant B cells, addressing antigen escape in relapsed/refractory B-ALL and B-cell NHL.
drug_name
CD19-BAFF Targeted CAR T-cells
nct_id_drug_ref
NCT06346912